3rd Quarter - Report

340B HEALTH for 340B HEALTH

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$161,917
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report (this page) Oct 17, 2008 $161,917 Replaced
3rd Quarter - Amendment Aug 20, 2009 $161,917 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

HR 2606 and S 1376. Extending 340B Drug Pricing to Inpatient Setting in DSH Hospitals and improving program integrity. Preserving current 340B Patient Definition Opposition to new regulations regarding physician administered drugs

LobbyistCovered position, as disclosed
MARISA SCHRADER CONWAY (No longer with organization)
STUART YAEL GORDON New —
ANNA MANGUM LA for Reps Viscloskey and Fascell 88-91
ROBERT RECKLAUS COS for Rep. Carolyn McCarthy 02-08
TED SLAFSKY Fellow for Sen. Dem. Policy Committee 1994
JAIMIE VICKERY LA for Reps Horn and Biggert 2000-05
WILLIAM VON OEHSEN —
BONNIE WEINTRAUB —

Contacted: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Office of Management & Budget (OMB); SENATE

Bills named: H.R. 2606 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.